This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Brolucizumab intraocular


Single use pre-filled syringe containing brolucizumab.

Drugs List

  • BEOVU 19.8mg/0.165ml solution for injection pre-filled syringe
  • brolucizumab 19.8mg/0.165ml solution for injection pre-filled syringe
  • Therapeutic Indications


    Treatment of neovascular age-related macular degeneration
    Treatment of visual impairment due to diabetic macular oedema



    Neovascular (wet) age-related macular degeneration (AMD)
    Initial dose
    6mg once every 4 weeks, for 12 weeks.

    No disease activity after 16 weeks
    6mg every 12 weeks.

    Disease activity after 16 weeks
    6mg every 8 weeks.

    Visual impairment due to diabetic macular oedema (DME)
    Initial dose
    6mg once every 6 weeks, for the first 5 doses.

    No disease activity after 5 doses
    6mg every 12 weeks.

    Disease activity after 5 doses
    6mg every 8 weeks.


    For intravitreal injection only.

    The intravitreal injection should be carried out under aseptic conditions.

    The interval between doses during maintenance treatment should not be less than 8 weeks to reduce the risk of intraocular inflammation including retinal vasculitis and retinal vascular occlusion, which has a higher incidence with shorter dosing intervals.


    Children under 18 years
    Ocular infection
    Ocular inflammation
    Periocular infection
    Recent ocular surgery

    Precautions and Warnings

    Females of childbearing potential
    Risk factors for retinal pigment epithelial tears
    History of cerebrovascular accident
    History of transient ischaemic attack
    Uncontrolled glaucoma
    Within 3 months of a myocardial infarction

    Suspend treatment if planned surgery within next 28 days
    Advise visual disturbances may affect ability to drive or operate machinery
    Aseptic technique should be used throughout
    Do not start therapy for 28 days post surgery, or until wound has healed
    Protect anaesthetised eye from dust and bacterial contamination
    Record name and batch number of administered product
    Treatment to be administered by or under supervision of specialist
    Vary injection site during prolonged therapy
    Monitor intra-ocular pressure post injection and manage appropriately
    Monitor visual acuity during and after treatment
    Advise patient to report any symptoms of endophthalmitis immediately
    Advise patient to report any symptoms of retinal detachment immediately
    Advise patient to report any unexpected changes in eye symptoms immediately
    Discontinue if intraocular inflammation or retinal vascular occlusion occur
    Discontinue if rhegmatogenous retinal detachment or stage 3/4 macular holes
    Suspend if best-corrected visual activity declines by 30 letters or more
    Suspend treatment if central foveal haemorrhage
    Suspend treatment if foveal haemorrhage >50% of the total lesion area
    Suspend treatment if intraocular pressure of >29 mmHg
    Suspend treatment if retinal break or tear develops
    Female: May cause infertility
    Female: Contraception required during and for 1 month after treatment
    Breastfeeding: Do not breastfeed during & for 1 month after treatment

    Brolucizumab should not be administered concurrently with other anti-VEGF medicinal products (systemic or ocular).

    A higher number of intraocular inflammation events were observed among patients with treatment-emergent antibodies. After investigation, retinal vasculitis and/or retinal vascular occlusion were found to be immune-mediated events. Intraocular inflammation, including retinal vasculitis and/or retinal vascular occlusion, may occur following the first intravitreal injection and at any time of treatment. These events were observed more frequently at the beginning of treatment.

    Pregnancy and Lactation


    Use brolucizumab with caution during pregnancy.

    The manufacturer recommends brolucizumab is not used during pregnancy unless the potential benefit to the mother outweighs the potential risk to the foetus. There are no or limited amount of data from the use of brolucizumab in pregnant women. Animal studies are insufficient to determine reproductive toxicity. After ocular use, systemic exposure to brolucizumab is low, but there is a potential risk to embryofoetal development. Brolucizumab should not be used during pregnancy unless the potential benefit to the mother outweighs the potential risk to the foetus.


    Brolucizumab is contraindicated during breastfeeding.

    The manufacturer advises that brolucizumab is not recommended when breastfeeding and for at least 1 month after the final dose. It is not known whether brolucizumab is excreted in human milk, therefore a risk to the infant cannot be excluded.

    Side Effects

    Abnormal sensation in eye
    Anterior chamber flare
    Anterior chamber inflammation
    Blurred vision
    Conjunctival haemorrhage
    Conjunctival hyperaemia
    Corneal abrasion
    Corneal oedema
    Detachment of the retinal pigment epithelium
    Eye pain
    Hypersensitivity reactions
    Increased intra-ocular pressure
    Increased lacrimation
    Ocular inflammation
    Punctate keratitis
    Reduced visual acuity
    Retinal artery occlusion
    Retinal detachment
    Retinal haemorrhage
    Retinal pigment epithelial tear
    Retinal tear
    Retinal vascular occlusion
    Retinal vasculitis
    Vitreous detachment
    Vitreous haemorrhage


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: December 2021

    Reference Sources

    Summary of Product Characteristics: Beovu 120 mg/ml solution for injection in pre-filled syringe. Novartis Pharmaceuticals UK Ltd. Revised April 2022.

    NICE Evidence Services Available at: Last accessed: 08 December 2022

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.